Pharmacological Targeting of IRE1 in Cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Inositol requiring enzyme 1 alpha (IRE1α) is a central mediator of the unfolded protein response (UPR).
• IRE1α exhibits significant protumoral functions in various cancers, with elevated activity correlating to poor patient prognoses.
• These findings highlight IRE1α as a promising therapeutic target for cancer treatment.

Purpose of the Study:

• To summarize recent advancements in the pharmacological targeting of IRE1α.
• To review the identification and optimization of IRE1α inhibitors.
• To discuss the mode of action, limitations, clinical challenges, and opportunities of IRE1α-modulating strategies.

Main Methods:

• Literature review of recent studies on IRE1α inhibitors.
• Analysis of drug discovery and development strategies targeting IRE1α.
• Discussion of preclinical and clinical data related to IRE1α inhibitors.

Main Results:

• Several strategies for IRE1α inhibition, targeting its kinase or RNase domains, have been developed.
• The identification and optimization of specific IRE1α inhibitors have been achieved.
• The efficacy and limitations of these inhibitors as anticancer agents are being evaluated.

Conclusions:

• Targeting IRE1α presents a viable therapeutic strategy for various cancers.
• Further research is needed to overcome challenges and optimize IRE1α-modulating therapies for clinical application.
• IRE1α inhibitors offer potential for improved cancer treatment outcomes.